Cocrystal Pharma, Inc. · NASDAQ:COCP
Cocrystal Pharma — Investor Presentation (June 2019)
30 slides from Cocrystal Pharma's investor presentation, Jun 4, 2019
Slide 1: Cocrystal Pharma Investor Presentation June 2019
CCRYSTAL Investor Presentation PHARMA,INC. June 2019
Slide 2: Forward Looking Statements
~ ( Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding expected results of our collaboration with Merck Sharp & Dohme Corp. (“Merck”) and expected funding by Merck
Slide 3: Cocrystal's Seasoned Senior Leadership
Ake Lot Cocrystal’s Seasoned Senior Leadership Manageme! Gary Wilcox, Ph.D. Chairman and Chief Executive Officer + Over 35 years of executive biotech leadership experience and played a key role in the development of Cialis Sam Lee, Ph.D. President + Over 20 years of anti-infective drug discovery res
Slide 4: Corporate Overview
Ake Corporate Overview IGt com Clinical Stage Antiviral Company Influenza Proprietary Drug Hepatitis Discovery Platform Merck Influenza Collaboration Norovirus Gastroenteritis
Slide 5: Technology and Drug Discovery Platform
mS Lot Technology and Drug Discovery Platform Technology Platform Drug Discovery Platform Based on Nobel Prize-winning technology + Near-atomic resolution Crystal Production Expression& Purification + X-ray quality crystal production High Throughput X-ray Crystallography Xray Diffraction + Drug pock
Slide 6: Robust Development Pipeline
\ ( Robust Development Pipeline Program Discovery Phase1 Phase2a | Phase2b Phase3 Partner CC-31244— Hepatitis ¢ (Pan-genotypic NS5B NNI) (HeV) CC-31244 - Hong Kong (Pan-genotypic NS5B NNI) (nfuenze > (Influenza A PB2 Inhibitor) InfluenzaABinhibitor > > merck 7 Noro Polymerase Norovirus inhibitor —!
Slide 7: Merck/Cocrystal Team Initiates Influenza Collaboration
Ake Lot Merck/Cocrystal Team Initiates Influenza Collaboration Received $4 million upfront payment, eligible to receive up to $156 million in milestone payments and royalties (undisclosed) on product sales Exclusive license and collaboration agreement to discover and develop certain proprietary infl
Slide 8: Antiviral Programs: Hepatitis C
Overview | Antiviral Programs: Hepatitis C
Slide 9: Cocrystal's HCV Strategy
\ ( Cocrystal’s HCV Strategy Lead program CC-31244, in ongoing Phase 2a study for the treatment of Hepatitis C Current HCV Market Overview AbbVie’s Mavyret™ Demonstrated Shorter Treatment * Clinical limitations of existing long-term HCV * Approved broad spectrum HCV combination therapy therapies: sh
Slide 10: HCV Is Still a Global Issue
RAS Lol HCV Is Still a Global Issue 71 Million oN) people die annually i 1 people infected globally (a APIS Only 20% Only 2% of infected patients of infected patients have been diagnosed! are being treated’ 1: Polaris Observatory, 2019 10
Slide 11: Hepatitis C Treatment Market Share
Ake Lot Hepatitis C Treatment Market Share 2017 Annual Sales: $12.69 Billion 2018 Annual Sales: $8.3 Billion = Gilead (Harvoni, Epclusa, Sovaldi, Vosevi) = Merck (Zepatier) m J&J (Olysio) m AbbVie (Viekira, Mavyret) mAbbVie (Viekira, Mavyret) = Gilead (Harvoni, Epclusa, Sovaldi, Vosevi) = Merck (Zep
Slide 12: CC-31244: Broad Spectrum HCV Non-Nucleoside Inhibitor
Akt ; a }@( CC-31244: Broad Spectrum HCV Non-Nucleoside Inhibitor (NNI) ~ Next Wave Combination Therapy HCV GT1—GT6 NS5B Polymerase Crystals + Potential best-in-class HCV NNI with a strong profile « Broad spectrum, potent NSSB polymerase inhibitor ie * High barrier to drug resistance + Effective aga
Slide 13: Potential Best-in-Class NNI
ae }@1 Potential Best-in-Class NNI xT CC-31244 > Genotypes 1-6 > 400 => (3.0) ABT-333 (Dasabuvir)' Genotype 1 400 BID (1.08) 800 BID (0.95) GS-9190 (Tegobuvir) Genotype 1 40 BID (1.0) 120 BID (1.5) 1. Represents approved DAA 13
Slide 14: CC-31244: Phase 2a University of Maryland Study Design
Ake Lot CC-31244: Phase 2a University of Maryland Study Design Open-label, Phase 2a study evaluating the safety, tolerability and preliminary efficacy of CC-31244 with approved HCV DAAs (HCV GT1 subjects, N=12) Sofosbuvir and Follow-Up at Velpatasvir 12 & 24 Weeks @o———- 4 Weeks ——_® CC-31244 (400 m
Slide 15: University of Maryland Phase 2a Interim Data
Ake Lot University of Maryland Phase 2a Interim Data On January 22, 2019, Cocrystal Pharma announced safety and preliminary efficacy data for its U.S. Phase 2a study evaluating CC-31244 for the ultra-short treatment of HCV infected individuals: All subjects completed the 6-week treatment regimen The
Slide 16: CC-31244: Ongoing Phase 2a Hong Kong Study
Ake Lot CC-31244: Ongoing Phase 2a Hong Kong Study Investigator IND; Dr. George Lau, Humanity & Health Research Centre, Hong Kong, China Open-label, safety, tolerability and preliminary efficacy of CC-31244 in combination with sofosbuvir and daclatasvir with or without a protease inhibitor, for the
Slide 17: Antiviral Programs: Influenza
17 Overview | Antiviral Programs: Influenza
Slide 18: Significant Unmet Need in Growing Influenza Market
Ake Lot Significant Unmet Need in Growing Influenza Market Global influenza market was valued at nearly $5.6 billion in 2017 and is expected to reach nearly $6.5 billion by 2022' Seasonal and pandemic infection 3-5 Million cases of severe illness annually" 1 Billion Up to 650,000 cases annually? dea
Slide 19: Influenza Remains a Major Global Concern
aS Lot Influenza Remains a Major Global Concern Flu season deaths top 80,000 last year, CDC says September27, 2018 Ehe New York Cimes ABARP™ 1 Pests on the oxt4.2018 | | \ AP News = : bee L208 This Flu Season Is the Worst in Rise For Older Americans Nearly a Decade Jan. 26,2018 CDC: Pediatric flu de
Slide 20: Influenza Drug Candidates
Ake Lot Influenza Drug Candidates Influenza A/B Inhibitor Svat? Proprietary Influenza A and B Crystals «3 MERCK Collaboration ¢ Broad spectrum, potent dual influenza A/B preclinical lead will be developed « Results of Cocrystal’s drug discovery platform technology « Binds to highly conserved site of
Slide 21: Influenza Drug Candidates
Ake Lot Influenza Drug Candidates Antiviral Product Candidates Target All Strains of the Influenza A Virus a ON Binds to the highly conserved m7GTP binding pocket of PB2 Influenza A/B Inhibitor Influenza PB2 Crystals Exhibits broad spectrum activity against seasonal and pandemic influenza strains, E
Slide 22: Antiviral Programs: Norovirus
22 Overview | Antiviral Programs: Norovirus
Slide 23: Norovirus Is an Area of Significant Unmet Need
uN ( Norovirus Is an Area of Significant Unmet Need Norovirus Market Overview Known Causes of Foodborne Illness Outbreaks, « No approved antiviral drugs for the treatment of Noro infection Parasites 1% Other Norovirus $4.2 billion in direct health system costs’ pas 700 million 19-21 million cheryl i
Slide 24: Cocrystal's Norovirus Program
Ake Lot Cocrystal’s Norovirus Program Norovirus Polymerase NNI Lead sel lia Ongoing Noro Polymerase NNIs Potential first-in-class NNI Norovirus and oraalk Polymerase Crystals Potent and broad spectrum anti-Noro polymerase inhibitors Toolbox complete - Noro, Norwalk, and mouse Noro polymerase crystal
Slide 25: Intellectual Property
Ake Lot Intellectual Property Patents and pending applications in the areas primarily related to the treatment of HCV, influenza A and influenza A/B * HCV Treatment * NS5B (non-nucleoside inhibitor) « Issued patents in U.S. « Pending applications in U.S., Australia, Brazil, Canada, China, Europe, Eu
Slide 26: Well-Positioned for Growth
26 Well-Positioned for Growth
Slide 27: Financial Snapshot
YT Financial Snapshot: NASDAQ: COCP ~$73M 31.6MM ~9K Common shares Average daily 1 METER GID outstanding volume’ 9 Capitalization Table (As of May 31, 2019) # of Shares WAEP ee Common Shares Outstanding (Directors, Officers and 15,214,178 46.19% Affiliates) Common Shares Outstanding (Other) 16,406,4
Slide 28: Strategy Directed at Advancing Programs and Growing Value
Ake Lot Strategy Directed at Advancing Programs and Growing Value ¢ Growth in focused therapeutic areas * Continue to build an innovative pipeline ¢ Form additional strategic collaborations and partnerships * Ongoing collaboration with Merck expected to accelerate influenza drug development program
Slide 29: Upcoming Milestones Expected to Drive Value
mS J}@( Upcoming Milestones Expected to Drive Value ~F Date Segment Event Achieved Q12019 Hepatitis C Phase 2a USA — Interim Results vY Q1 2019 Hepatitis C Phase 2a (Hong Kong)- First Patient Commencement oS Q2 2019 Influenza A Commence GLP Toxicology Studies Q42019 Hepatitis C Phase 2a (Hong Kong)
Slide 30: Thank you!
C¥CRYS TA L Thank you! PHARMA,IN